Biocancell is readying a Phase IIb clinical trial of BC-819 to test its safety and efficacy when given in conjunction with chemotherapy.
Biocancell Therapeutics Ltd. (TASE:BICL) has obtained US Food and Drug Administration (FDA) fast-track approval for pancreatic cancer treatment, BC-819.
Biocancell is readying a Phase IIb clinical trial of BC-819 to test its safety and efficacy when given in conjunction with Gemcitabine, the standard chemotherapy for pancreatic cancer.
Biocancell's share price rose 7.1% to NIS 1.47, giving a market cap of NIS 39 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 4, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011